טוען...
Isoagglutinin Reduction in Human Immunoglobulin Products by Donor Screening
INTRODUCTION: Hemolysis is considered a class effect and a rare adverse event that can occur following therapy with human normal immunoglobulin for intravenous administration [i.e., intravenous immunoglobulin (IVIG)]. Anti-A/B isoagglutinins (also referred to as isohemagglutinins) originating from d...
שמור ב:
| הוצא לאור ב: | Biol Ther |
|---|---|
| Main Authors: | , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Springer Healthcare
2014
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4254866/ https://ncbi.nlm.nih.gov/pubmed/24841428 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13554-014-0016-2 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|